PTCT Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -54.2% compared to PTC Therapeutics's net margin of -43.9%. PTC Therapeutics's return on equity of -- beat Blueprint Medicines's return on equity of -50.13%.

PTC Therapeutics has a consensus price target of --, signalling upside risk potential of 28.87%. On the other hand Blueprint Medicines has an analysts' consensus of $125.58 which suggests that it could grow by 39.02%. Given that Blueprint Medicines has higher upside potential than PTC Therapeutics, analysts believe Blueprint Medicines is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.629, which suggesting that the stock is 37.101% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.419%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $196.8M, which are larger than Blueprint Medicines quarterly revenues of $128.2M. PTC Therapeutics's net income of -$106.7M is lower than Blueprint Medicines's net income of -$56.3M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 3.87x versus 13.04x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

ClearPoint Neuro has a net margin of -54.2% compared to PTC Therapeutics's net margin of -61.24%. PTC Therapeutics's return on equity of -- beat ClearPoint Neuro's return on equity of -64.36%.

PTC Therapeutics has a consensus price target of --, signalling upside risk potential of 28.87%. On the other hand ClearPoint Neuro has an analysts' consensus of -- which suggests that it could grow by 16.2%. Given that PTC Therapeutics has higher upside potential than ClearPoint Neuro, analysts believe PTC Therapeutics is more attractive than ClearPoint Neuro.

PTC Therapeutics has a beta of 0.629, which suggesting that the stock is 37.101% less volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 1.084, suggesting its more volatile than the S&P 500 by 8.385%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $196.8M, which are larger than ClearPoint Neuro quarterly revenues of $8.1M. PTC Therapeutics's net income of -$106.7M is lower than ClearPoint Neuro's net income of -$5M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 3.87x versus 12.64x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -54.2% compared to PTC Therapeutics's net margin of 25.23%. PTC Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

PTC Therapeutics has a consensus price target of --, signalling upside risk potential of 28.87%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that PTC Therapeutics has higher upside potential than Pfizer, analysts believe PTC Therapeutics is more attractive than Pfizer.

PTC Therapeutics has a beta of 0.629, which suggesting that the stock is 37.101% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. PTC Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $196.8M, which are smaller than Pfizer quarterly revenues of $17.7B. PTC Therapeutics's net income of -$106.7M is lower than Pfizer's net income of $4.5B. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 3.87x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -54.2% compared to PTC Therapeutics's net margin of 37.71%. PTC Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

PTC Therapeutics has a consensus price target of --, signalling upside risk potential of 28.87%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 21.8%. Given that PTC Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe PTC Therapeutics is more attractive than Vertex Pharmaceuticals.

PTC Therapeutics has a beta of 0.629, which suggesting that the stock is 37.101% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $196.8M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. PTC Therapeutics's net income of -$106.7M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 3.87x versus 9.93x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.